Policy & Regulation2026-04-24
Usona Institute Awarded FDA Commissioner's National Priority Voucher for PSIL201 Psilocybin in Major Depressive Disorder
FDA awarded a Commissioner's National Priority Voucher (CNPV) to Usona Institute for PSIL201, a psilocybin treatment in Phase 3 for major depressive disorder. The award was announced concurrently with the Compass and Transcend CNPVs.
